Compare Duolingo Inc (DUOL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs IDEXX Laboratories, Inc. — how do they compare? Duolingo Inc trades at $150.02 (market cap $7.08B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.7× Duolingo Inc's market cap, and Duolingo Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DUOL | IDXX | |
|---|---|---|
Market Cap | $7.08B | $40.43B |
Volume | 729,171 | 692,164 |
Sector | Technology | Health |
52-Week High | $341.08 | $766.68 |
52-Week Low | $90.03 | $504.70 |
Typical Hold Time | 137 Days | 46 Days |
Enterprise Value | $5.85B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.16, down 0.37% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamental momentum with Q2 2026 EPS of $0.66 beating expectations of $0.604, marking the third consecutive quarterly beat. Revenue growth remains robust at 29% year-over-year, supported by a 36% net income margin. Technical indicators show a bullish trend with the stock trading above key support levels, though RSI suggests potential near-term overbought conditions.
Duolingo's outlook remains positive with accelerating revenue growth and expanding profitability, though the stock trades at a premium valuation with a P/E of 17.87. Key risks include CEO share sales and competitive pressures in the edtech space. Analyst consensus leans cautious with 37.5% buy ratings versus 54.2% hold, suggesting potential for re-rating if growth momentum continues.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
